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Abstract
Thyroid nodules are frequent in general population, found in 3.7–7% of people by palpa-
tion and 42–67% by ultrasonography (US). The differential diagnosis ranges from papil-
lary (PC), follicular (FC) and medullary (MC) carcinomas to follicular adenoma (FA) and 
colloid goitre. Cancer risk in thyroid nodules varies: 5% in masses found by palpation, 
1.6–15% by US, 3.9–11.3% by computed tomography (CT), 5–6% by magnetic resonance 
imaging (MRI) and 30–50% by positron emission tomography (PET). The final diagnosis 
depends on fine needle aspiration (FNA) findings and histopathology. The recent WHO 
classification (2017) is based on classic morphology, including assessment of invasion 
and nuclei. New entities are defined to designate tumours with doubtful invasion or 
controversial nuclear features. By immunohistochemistry, PC expresses HBME-1, TROP-
2, CITED1 and CK19. Notably, PC can stain for CD20. MC is recognised by neuroendo-
crine  differentiation. To distinguish FA vs. FC, evaluation of HBME-1, p27 and galectin  
has been suggested. Regarding miRNAs, miR-146b, miR-222, miR-221 and miR-181b 
are upregulated, while miR-145, miR-451, miR-613 and miR-137 are downregulated in 
PC. FC features downregulated miR-199a-5p and upregulated miR-197 and miR-346. In 
MC, miR-21 and miR-129-5p are downregulated. In addition, increased systemic inflam-
matory reaction can be poor prognostic factor in thyroid cancer. The aim of this chapter is 
to review classic and innovative histopathology of thyroid nodules for diagnostic pathol-
ogy practice and research in multidisciplinary thyroid teams.
Keywords: thyroid nodule, thyroid carcinoma, papillary carcinoma, follicular 
carcinoma, medullary carcinoma, histopathology, immunohistochemistry, miRNA, 
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1. Introduction
Thyroid nodules represent an extremely frequent finding in the general population [1] and 
therefore enter the spectrum of the most common diagnostic dilemmas in endocrine sur-
gery, cytology and surgical pathology. By palpation, such nodules can be found in 3.7–7% 
of general population, more frequently in females: 6.4% contrasting with 1.5% in males [2]. 
Three quarters of palpable nodules are solitary [3], raising increased suspicion of neoplasm. 
By ultrasonography (US), thyroid nodules can be disclosed even more frequently: in 42–67% 
of patients, and other radiological investigations also yield incidental nodules in a significant 
proportion of cases [2, 4–6] as shown in Table 1.
Malignant tumours do occur in thyroid albeit infrequently and can present as an incidentally 
found thyroid nodule (Table 1); therefore, reliable investigation is mandatory. The differen-
tial diagnostic approach should not be formal as evidence from a tertiary referral centre indi-
cates that incidentally found thyroid carcinomas are even more frequently associated with 
lymphatic invasion and lymph node metastases [7]. However, the discrimination between 
malignant and benign thyroid masses can be difficult at all levels—radiology, fine needle 
aspiration (FNA) cytology and histopathology.
On the other hand, overdiagnosis of malignancy would lead to an unnecessary operation, 
carrying risks of complications. For instance, in a large group of 27,912 patients, included in 
the Surveillance, Epidemiology and End Results (SEER)-Medicare database, thyroid surgery-
specific complications developed in 12.3% cases, while general postoperative complications 
were seen in 6.5% of patients [9]. Among the specific complications, hypoparathyroidism and 
vocal cord paralysis are the most frequent. The frequency of hypoparathyroidism in differ-
ent studies ranges from 0.5 to 65% [10]. Transient hypoparathyroidism has been observed 
in 28.4–44.2% of patients, and 0.3–1.1% developed permanent hypoparathyroidism [11, 12]. 
After total thyroidectomy for well-differentiated thyroid carcinoma in 5670 SEER-Medicare 
patients (1991–2009), the frequency of unilateral vs. bilateral vocal cord paralysis was 8.2 vs. 
1.3% [13]. Postoperative hematoma develops in 0.1–1% of patients and can lead to airway 
compression [14]. In addition, lifelong thyroid replacement treatment [15] is unavoidable 
after thyroidectomy. Psychological concerns and additional financial burden must be consid-
ered as well.
Evaluation method of the thyroid 
gland
Frequency of thyroid 
nodule, %
Cancer risk in the identified 
nodule, %
References
Palpation 3.7–7 5 [2]
Ultrasonography 42–67 1.6–15 [2, 8]
Computed tomography 16 3.9–11.3 [2]
Magnetic resonance imaging 4.5–5.1 5–6 [4–6]
Positron emission tomography 1.6 (for solitary pattern) 30–50
34.8 in meta-analysis
[2]
Table 1. Frequency of thyroid nodule and risk of malignancy by the method of investigation.
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The rate of surgical complications is decreasing [13] due to novel approaches including 
continuous intraoperative neuromonitoring [10, 16, 17], novel haemostatic equipment, e.g., 
advanced bipolar electrocautery, ultrasound or hybrid devices and haemostatic agents for use 
close to vulnerable structures [14]; evaluation of surgeons’ experience [18] and implementa-
tion of carbon nanoparticles to identify parathyroid glands [12, 19]. However, unnecessary 
surgery must be avoided. This, in turn, places greater demands on preoperative diagnostics, 
including immunohistochemical and/or molecular evaluation within the frames of multidisci-
plinary approach. Thus, the aim of this literature review is to summarise the present evidence 
in diagnostic pathology of thyroid nodules for the needs of practising pathologists as well as 
other colleagues working in multidisciplinary thyroid teams.
2. Epidemiology of thyroid carcinoma
The global incidence of thyroid cancer in 2012 was estimated as 6.1 per 100,000 women and 1.9 
per 100,000 men. The gender-specific mortality rates were assessed as 0.6 and 0.3 per 100,000 
respectively [20]. Generally, the epidemiology of thyroid carcinoma is characterised by grow-
ing incidence, decreasing global mortality and predominance of papillary carcinoma (PC). PC 
constitutes 65–93% of thyroid carcinomas [21, 22], while follicular carcinoma (FC) is respon-
sible for 6–10% of thyroid carcinoma cases [21, 23]. Medullary carcinoma (MC) accounts for 
2–5% of thyroid carcinomas [21, 24].
The incidence of thyroid cancer is growing in most countries and in both genders [20, 25], 
e.g., increasing from 4.9 to 14.3 per 100,000 individuals in USA over time period between 1975 
and 2009 [26]. In the time period between 2000 and 2010, thyroid cancer-induced mortality 
in males has decreased in most European countries. However, it has increased significantly 
in Moldova (for 49.9%), Latvia (26.2%) and Portugal (15.7%). Regarding Americas, significant 
increase in mortality was seen in Costa Rica (66.9%), Uruguay (47.9%) and Ecuador (36.3%), 
while moderate – in USA (8.1%). New Zealand has also experienced increase in thyroid can-
cer-induced male mortality (14.5%). Regarding females, mortality from thyroid cancer has 
increased in Greece (13.3%), Colombia and Ecuador (both 17.8%), USA (6.8%) and Australia 
(14.0%). The 2008–2012 mortality levels were highest in Latvia, Estonia, Hungary, Moldova 
and Israel for males and in Ecuador, Colombia, Israel, Mexico and Latvia for females [20].
The growing incidence of thyroid carcinoma parallels increasing frequency of PC [26] and 
especially papillary microcarcinoma. Therefore, part of the scientific world considers the 
increase in incidence as the result of better diagnostics, yielding more incident nodules and 
enabling evaluation by US and biopsy even in as small lesions as measuring 2 mm in diam-
eter. However, SEER-based data have clearly disclosed increased incidence of large PC as 
well. This corroborates the opinion that incidence growth purely reflects better diagnostics 
and incidental findings [2] and suggests true growth of incidence. In addition, incidental 
thyroid nodules are less frequently reported in clinical practice than in research. In a large 
retrospective analysis of 97,908 radiological reports, carried out in Chicago, USA, such nod-
ules were noted in 0.4%, including 0.14% of computed tomography (CT), 0.64% of magnetic 
resonance imaging (MRI), 0.36% positron emission tomography (PET) scans and 6.59% US 
examinations. In contrast, on dedicated review, nodules were found in 10% of CT scans [27]. 
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The reporting pattern is highly variable, depending both on nodule size and radiologist’s 
specialisation [28]. Thus, the real input of incidental nodules in the growing incidence may 
be moderate.
The true increase of the incidence of thyroid carcinoma can be attributed to several risk fac-
tors, including changes in iodine supplement [25], adiposity [29, 30], oestrogens [31, 32], parity 
[33, 34], pregnancy-related increases in TSH levels [25], ionising radiation [35], and chemi- 
cals, e.g., polybrominated diphenyl ethers that are or have been used as flame retardants [25].
Many authors accentuate the gap between stable death rates and increasing numbers of new 
thyroid carcinoma cases suggesting “overestimation” of thyroid cancer [15], mainly small 
indolent PCs [20]. Existence of self-limiting thyroid cancers has been hypothesised based on: 
(1) lack of mortality reduction by surgery for papillary microcarcinoma; (2) low growth rate 
of papillary microcarcinoma and (3) high prevalence of papillary microcarcinoma in young 
people, contrasting with higher mortality in middle-aged patients. The consequences of this 
point of view include the conclusion that “the early detection of self-limiting cancers results in 
over-diagnosis” [36]. Possibly, most patients may not need treatment but those with high-risk 
disease must be promptly distinguished [20].
3. Radiological evaluation of a thyroid nodule
Neck US is the essential method in thyroid evaluation [37]. It can be both the starting point 
disclosing an incidental nodule and a reliable source of significant information for the final 
diagnosis. Thyroid nodule can be identified if US is performed for palpable neck mass, 
lymphadenopathy, suspected parathyroid or vascular pathology. The yield of thyroid nod-
ules in such patients is 42–67%. In patients evaluated by cervical US for parathyroid disease, 
thyroid nodules are found in 20–56%, and the frequency of cancer in these lesions is 2–6%. 
By carotid artery duplex US, thyroid nodules have occasionally been more frequent (28%) 
than significant carotid stenosis (13%); the frequency of cancer in these nodules was 7.4%. 
The benefits of US include exact size measurements and possibility to disclose the features 
of malignant growth: hypoechoic nodule with irregular borders, central hypervascularity, 
presence of microcalcifications and elongated shape being taller than wide. US-guided FNA 
should be performed if the nodule exceeds the size of 1 cm or has additional worrisome fea-
tures. Cancer risk in an incidental thyroid nodule, found by US, is 15% (not counting papillary 
microcarcinoma), being three times higher than in palpable nodule [2].
The innovations in ultrasonography include contrast-enhanced ultrasonography, elastogra-
phy and superb microvascular imaging [1, 38, 39].
Computed tomography has a limited role in thyroid pathology. It is more informative in the 
beginning of the diagnostic way and in special situations. CT can provide the first evidence 
of thyroid nodule. In patients undergoing radiological examination for non-thyroid disease, 
cervical and thoracic CT yields thyroid nodules in up to 16% of cases. The risk of malignancy 
in CT-detected nodule ranges between 3.9 and 11.3%. Several pitfalls limit the informativity 
of CT in thyroid disease. These include the assessment of nodule size, number of lesions and 
risk of cancer. In studies comparing CT, US and postoperative findings, CT was shown to be 
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less informative than US although both methods correlated with the findings in resected tis-
sues. The size is the only reliable predictor of malignancy in CT, while presence of microcal-
cifications and attenuation in Hounsfield units are not specific. Because of these limitations, 
thyroid CT should be followed by US. CT can be useful in the further assessment of advanced 
cases to detect retrosternal spread, invasion into trachea and/or large vessels, metastases and 
recurrence in the site of operation, lymph nodes or distant tissue [2, 40].
Positron emission tomography usually is not included in the primary evaluation of thyroid. 
However, PET is increasingly performed for surveillance and staging of other malignant 
tumours. Occasionally, increased uptake in the thyroid has been noted in these patients. PET-
positivity in the thyroid can manifest as diffuse uptake throughout the whole gland or as a 
solitary focus. The diffuse pattern is characteristic for Hashimoto thyroiditis or Graves’ disease 
and carries low risk of malignancy: 4.4% comparable with 5% risk in palpable nodules. In con-
trast, solitary focus is a rare but worrisome finding: it is seen only in 1.6% of examined patients 
but the risk of malignant tumour reaches 30–50% (34.8% in a meta-analysis) as described by 
Wilhelm [2]. Therefore, US and FNA of a PET-positive focus are suggested regardless of size [2].
4. Histology and immunohistochemistry: From classics to 
innovations
4.1. Follicular adenoma
Follicular adenoma (FA) is defined as a benign, encapsulated, non-invasive thyroid tumour 
differentiating towards follicular epithelium and lacking the nuclear features of papillary thy-
roid carcinoma.
By autopsy findings, FAs have been reported in 3–5% of adults. Not surprisingly, this fre-
quency is close to the prevalence of palpable solitary thyroid nodules. The known risk factors 
of FA include radiation exposure, especially in childhood and adolescence, and lack of iodine. 
Radiation exposure can cause FA after prolonged latent period (10–50 years), and the relative 
risk can reach 15. The role of iodine deficiency has been substantiated on more frequent find-
ings of palpable thyroid nodules in areas of low iodine consumption. Although a fraction of 
such nodules will represent true FA, endemic sporadic goitre is classically triggered by iodine 
deficiency. Regarding hereditary factors, FAs are more frequent in patients having Cowden 
syndrome or familial adenomatous polyposis [3].
On US, FA represents a solid, well-demarcated, hypo- or isoechoic homogeneous mass. On 
radionuclide scan, most FAs are “cold” nodules, although “hot” adenomas are possible and 
can be associated by clinical hyperthyroidism [3].
FNA specimens from FA are characterised by high cellularity, rich presence of follicular cells, 
including microfollicles, and scant colloid. Macrofollicular FAs yield more colloid and mono-
layered sheets of epithelium. Inflammation, PC-type nuclei or psammoma bodies are absent. 
On FNA, differential diagnosis with follicular carcinoma is impossible as this would request 
identification of invasive growth. In addition, colloid-rich cytological specimens are similar 
to hyperplastic nodules [3].
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Grossly, FAs are solitary, rounded, grey, whitish, tan or brown masses with smooth outline, 
contrasting with normal surrounding thyroid tissues. Microscopic structure is variable, but 
several key features are observed: (1) origin from follicular epithelium, mostly reflected in 
the follicular architecture; (2) structural difference from surrounding tissues; (3) presence of 
complete fibrous capsule; (4) lack of invasion; (5) lack of PC nuclear features and (6) lack of 
neuroendocrine differentiation. The architecture can be follicular (normo-, micro- or macro-), 
solid or trabecular. The cells are cuboidal or polygonal but can be cylindrical in “hot” adeno-
mas. Cytoplasm is easily seen, eosinophilic or light. Nuclei are round, smooth, uniform, with 
evenly distributed, moderately dark chromatin. Mitoses are rare. Although stroma is usually 
scant, it can be more abundant in some tumours, exhibiting oedema, myxoid structure, haem-
orrhage, fibrosis and hyaline change as well as calcification. In distinction from hyperplastic 
nodule, solitary occurrence, presence of capsule and difference from surrounding thyroid 
tissues are helpful. In differential diagnosis with follicular carcinoma, lack of capsular and 
vascular invasion is the central criterion [3, 41].
FA has multiple histological variants including FA with papillary hyperplasia, lipoadenoma, 
FA with bizarre nuclei, signet ring cell FA, clear cell FA and spindle cell FA [3, 42].
4.2. Papillary thyroid carcinoma
Papillary carcinoma is a well-differentiated malignant thyroid tumour characterised by (1) ori-
gin from/differentiation towards follicular epithelium and (2) diagnostic nuclear features [22].
PC is the leading histological type of thyroid carcinomas, thus the risk factors are in line 
with the general risk factors of thyroid cancer, comprising ionising radiation, oestrogens, 
obesity, diabetes mellitus and ingestion of nitrates via food [22]. In contrast with FC, high 
iodine intake increases the risk of PC. Thus, iodine supplementation decreases the FC 
incidence and increases the PC occurrence. Despite higher PC frequency, the epidemio-
logical change might be considered beneficial due to the favourable prognosis of papillary 
carcinoma.
On US examination, PC is hypo- or isoechoic, solid or cystic, irregularly shaped nodule that 
is taller than wide, contains microcalcifications and features disorganised vascular supply. By 
scintigraphy, papillary carcinomas mostly are “cold” [22].
By FNA, high cellularity is characteristic. Architecturally, papillae or monolayer sheets can 
be observed. Psammoma bodies are present. The cells are tall, showing visible cytoplasm. 
Nuclear changes are the most characteristic and diagnostically most important findings. 
These include thickened nuclear membranes and chromatin clearing, nuclear grooves and 
pseudoinclusions. The colloid can be either watery or thick, so-called ropy colloid. It might be 
more difficult to recognise the follicular variant and columnar variant having scarce nuclear 
features. Multiple nuclear inclusions can be seen in tall cell variant resulting in “soap bubble” 
appearance of the nuclei. Squamous metaplasia is possible in diffuse sclerosing variant; how-
ever, typical nuclear features are also present [22].
Grossly, PC is seen as a white, hard mass with irregular outline. Cystic change can be pres-
ent while necrosis (in the absence of FNA history that might induce vascular collapse) is not 
characteristic and might indicate transformation to more aggressive tumour [22].
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Microscopically, PC is characterised by papillary architecture (Figure 1) and the diag-
nostic nuclear features. The papillae show significant variability between tumours, being 
straight or branched, loosely or tightly packed, long or short. Cystic or follicular foci are 
frequent. Solid and trabecular architecture can occur as well. Nuclei are enlarged, over-
lapping, elongated, characterised by membrane irregularity and optically empty “ground 
Figure 1. Papillary thyroid carcinoma. Note the characteristic architecture and nuclear features. Haematoxylin-eosin, 
original magnification 200×.
Figure 2. Stromal desmoplasia in papillary carcinoma. Haematoxylin-eosin, original magnification 100×.
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glass” appearance. The “ground glass” appearance is very helpful in diagnostic evalua-
tion of formalin-fixed, paraffin-embedded tissues. However, it is not seen in frozen sec-
tions compromising intraoperative assessment. The nuclear contour irregularity is seen 
as nuclear pseudoinclusions (of cytoplasm) and longitudinal grooves. Mitoses are rare. 
Psammoma bodies, present in 50% of cases, are small, rounded, laminated calcifications 
in stroma or lymphatic channels but not in colloid. Squamous metaplasia can be present. 
Stroma (Figure 2) is well developed [22, 41].
The histological variants of PC include papillary microcarcinoma (smaller than 1 cm; see Figure 
3), encapsulated, follicular, diffuse sclerosing, tall cell, columnar cell, cribriform morular, hobnail, 
solid, oncocytic, spindle cell, clear cell and Warthin-like variants as well as PC with fibromato-
sis-like stroma [22, 43]. Carcinomas showing true papillary architecture are dominated by BRAF 
(V600E) mutations, while tumours holding follicular architecture mostly carry RAS mutations [44].
4.3. Follicular carcinoma
Follicular carcinoma is a malignant thyroid epithelial tumour characterised by follicular dif-
ferentiation, invasive growth morphologically reflected in the invasion through capsule or 
into blood vessels and absence of the nuclear features of papillary carcinoma [23].
Figure 3. Papillary microcarcinoma in thyroid tissues. Haematoxylin-eosin, original magnification 50×.
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The risk factors include low iodine supply and ionising irradiation although the associa-
tion with radiation is weaker than for PC [23]. By FNA, FC cannot be distinguished from 
FA. Grossly, FCs are solid masses. Occasionally, the capsules seem thicker than in FA. Rarely, 
invasion through the capsule or into extrathyroid tissues is grossly evident.
Microscopically, the tumour is characterised by follicular architecture. By definition, there are 
no nuclear features that would define PC. The distinction from FA requires identification of 
invasion that can manifest as either minimal or wide capsular invasion (Figure 4) or angioin-
vasion (Figure 5). Minimal invasion is defined as focal, but unequivocal invasive growth that 
penetrates the full thickness of capsule. Irregular outline of the inner surface of the capsule or 
tumour cell groups within the capsule are insufficient for diagnosis. FC also must be strictly 
distinguished from artefacts such as surgery- or FNA-induced capsular lesions or curling of 
the tumour in the edges of tissue block. Vascular invasion must be assessed only in the capsule 
or extratumourally, not in the middle of the mass. To distinguish angioinvasion from artefac-
tual contamination of blood vessels by tumour cells, e.g., during grossing, any intravascular 
tumour cell group should be qualified as an evidence of invasion only if the tumour tissues are 
adherent to blood vessel walls, covered by either endothelium or fibrin, or thrombus [23, 41]. 
Morphologic variants are rare, including clear cell [23], signet ring cell [45], microcystic and 
spindle cell variants, FC with fat cells and FC with glomeruloid pattern [23]. Mucinous variant 
has been reported [46].
Figure 4. Follicular thyroid carcinoma. Note the invasion through the capsule. Haematoxylin-eosin, original 
magnification 200×.
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4.4. Follicular tumours with controversial morphology
In the recent WHO classification (2017), certain new entities have been defined to classify 
thyroid tumours with controversial morphological appearance, doubtful invasion or ques-
tionable nuclear features [47].
Follicular-patterned tumours showing unequivocal capsular or vascular invasion are desig-
nated as (1) invasive follicular variant of PC, if the nuclei show typical structure of PC; (2) well 
differentiated thyroid carcinoma, not otherwise specified, if the nuclear features are contro-
versial; and (3) FC, if the nuclei lack any traits of PC.
Tumours that are definitely non-invasive are designated FA, if the nuclear structure is certainly 
of non-papillary type. Otherwise, the diagnosis of non-invasive follicular thyroid neoplasm 
with papillary-like nuclear features is issued [48]. Finally, tumours with questionable invasion 
are designated either follicular tumours of uncertain malignant potential if the nuclei are of 
non-papillary type or well-differentiated tumour of uncertain malignant potential in all other 
cases.
These new entities provide pathologists with the long-awaited benefit of accurate diagnosis. 
However, the biological potential of these groups still remains to be assessed. Generally, the 
risk of recurrence or metastasis is low, but exceptions still have been reported [47].
4.5. Medullary carcinoma
Medullary carcinoma is a malignant thyroid tumour showing C-cell differentiation [49].
Figure 5. Invasion of a follicular thyroid carcinoma in a large blood vessel. Haematoxylin-eosin, original magnification 
50×.
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MC is characterised by high fraction of hereditary tumours, reaching up to 30%. In contrast, the 
risk factors of sporadic MC are almost unknown [49]. Activating RET mutations are present in 40% 
of sporadic MC and over 90% of hereditary cases, mostly with almost complete penetrance [50].
FNA shows round, ovoid or spindle cells. Eccentric position of the nucleus can impart plasma-
cytoid appearance. Chromatin is granular. Amyloid can be present in the specimen. Despite 
immunohistochemical investigation, diagnosis is correctly recognised in only 46.1% of cases 
[49]. In our experience, systematic immunohistochemical approach to all thyroid tumours 
lacking typical papillary type nuclei is helpful to avoid a diagnostic mistake. Serum calcitonin 
level would also disclose the diagnosis in most cases.
Grossly, the lesions are grey to yellow, featuring different consistencies. Bilateral and mul-
ticentric growth is characteristic for inherited tumours [49]. Microscopic picture can be very 
confusing due to the variety of histological patterns—MC is the “great mimic.” However, 
the immunophenotype is distinctive in most cases, and the presence of local amyloidosis can 
significantly guide the diagnostic thinking, enhancing the suspicion for MC.
The architecture of MC is solid, trabecular, lobular or insular. The cells are polygonal, plas-
macytoid, spindled or show mixed morphology. Nuclei are round, with coarse chromatin 
and small nucleoli. The cytoplasm ranges from eosinophilic to amphophilic. Calcitonin-
containing amyloid is present in 90% of cases. The presence of nuclear pseudoinclusions and 
rare psammoma bodies can be misleading. Hereditary tumours are accompanied by C cell 
hyperplasia. The variants include papillary, follicular, spindle cell, giant cell, clear cell, onco-
cytic, melanotic, squamous, amphicrine, paraganglioma-like, angiosarcoma-like, encapsu-
lated and small cell MC [41, 49, 51]. MC is characterised by neuroendocrine phenotype, and 
immunohistochemistry for chromogranin A, calcitonin or related peptides, and carcinoem-
bryonic antigen is highly advised to confirm the diagnosis.
4.6. Metastases to the thyroid gland
Metastases of extrathyroid tumours (MTS) to the thyroid gland are rare. In FNA cytology, 
MTS constituted 2.2% of cases [52]. However, they are encountered in diagnostic surgi-
cal pathology as well as in FNA cytology and can have very misleading morphology. The 
authors of a recent clinical series have reported on 32 such cases [53]. Among these patients, 
lung was the most frequent site of primary tumour (14/32), followed by renal and gastro-
intestinal cancers at equal frequency of 5/32. Interestingly, MTS affecting the thyroid were 
diagnosed over wide time range, from manifestation simultaneously with the primary can-
cer to delayed presentation 16 years after the initial diagnosis. Although thyroidectomy was 
not considered in patients affected by an aggressive cancer at high stage, it still has been 
performed in 34.5% of patients having secondary thyroid tumour, and the longest survival 
was 7 years [53]. 
The spectrum of MTS differs between hospitals, e.g., renal cell carcinoma (48.1%), colorec-
tal (10.4%), pulmonary (8.3%) and breast carcinoma (7.8%) as well as sarcomas (4.0%) were 
observed in German series [54]. Wide scope of primary tumours was disclosed in cytologically 
investigated cases, including pulmonary (6/20), gastrointestinal, breast (each 5/20), laryngeal 
(3/20) and renal cell (1/20) carcinoma [52]. 
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In the largest series of secondary thyroid tumours, comprising 97 patients who underwent 
FNA in Mayo Clinic, lung and kidney were the most frequent primary sites (22% each), fol-
lowed by head and neck cancer (12%) as reported by Hegerova et al. [55]. Similarly to the 
observations by Zhang et al. [53], prolonged survival was seen in some patients, reaching 
228 months (median, 20 months). Thyroid resection was not infrequent: it was performed 
in 41/97 patients reaching survival of 30 months (range, 3–171 months), while the median 
survival in non-operated patients was 12 months (range, 1–228 months). The difference was 
statistically insignificant [55]. 
Metastases of cutaneous or uveal melanomas have been reported and can present a major 
diagnostic problem considering that melanoma is another “great mimic” in pathology [56].
4.7. Immunohistochemistry of thyroid neoplasms
Although in most cases routine stains are sufficient for correct classification of a thyroid nod-
ule, ancillary methods are occasionally necessary. Immunohistochemistry (IHC) is a well-
known, easily applicable technology, nowadays complemented with automatization and 
digital evaluation. The expenses are moderate, making IHC a widely available approach. It 
benefits from high accuracy of antigen-antibody reaction and visual evaluation of the positive 
targets resulting in correct interpretation.
In thyroid pathology, several antigen groups have been explored. Antigens that are specific for 
thyroid follicular cells (thyroglobulin, TTF-1) are useful to identify the follicular origin of a neo-
plasm. Expression is observed in PC [22], FA [3] and FC [23] as well as in Hurtle cell tumours. 
MC is negative for thyroglobulin but can exhibit a weak staining for TTF-1 [49], although con-
troversial opinions have been expressed. A possible pitfall is nuclear expression of TTF-1 in 
non-squamous lung cancer MTS (adenocarcinoma, small cell carcinoma, large cell carcinoma). 
Lung cancer lacks thyroglobulin but can express surfactant apoprotein A (adenocarcinoma), 
napsin A (adenocarcinoma; however, positive reaction in thyroid cancers has been reported) 
or neuroendocrine markers (small cell carcinoma and large cell neuroendocrine carcinoma).
Neuroendocrine markers (chromogranin A, synaptophysin) along with calcitonin are charac-
teristic of MC [49] and C-cell hyperplasia. PC and FA are negative for chromogranin A, other 
neuroendocrine markers and calcitonin [3, 22].
Membrane proteins, including HBME-1, TROP-2, beta-galactoside-binding protein family 
galectins and glypicans (one of the two protein families within heparin sulphate proteoglycan 
class), are helpful in PC diagnostics. Cytoskeleton composition by certain intermediate filaments 
(cytokeratin (CK) 19, vimentin) also shows correlation with specific pathological processes. 
Proliferation activity in carcinomas is generally higher than in benign nodules but the levels in 
differentiated cancers are too low to set a reliable diagnostic threshold. Nevertheless, proteins 
that are involved in cell cycle regulation and apoptosis have been evaluated in thyroid pathology.
Hector Battifora mesothelial epitope, widely known by the abbreviation HBME-1, is a mem-
branous antigen, located on microvilli of benign and malignant mesothelial cells [57, 58]. In 
the thyroid, intense HBME-1 expression is characteristic for PC [22, 59]. Membranous pattern 
is the most specific [22]. Diffuse and intense membranous expression is strongly supportive for 
PC diagnosis [60]. A fraction of FC is positive [23], but reactivity in FA is considered rare [3].
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The reported expression rate of HBME-1 in PC ranges between 73.8% [61], 75.9% [62], 85.0% 
[63] and 96.1% [64]. Higher frequency has been found in classic PC, e.g., ranging between 
95.9 and 100% in contrast to 45.0–81.1% in follicular variants [61, 65]. However, some authors 
report close findings in classic or follicular variant. Thus, in a large IHC study of 127 thyroid 
tumours, including 49 classic PCs, 29 cases of follicular variant of papillary carcinoma (FVPC) 
and 49 FAs, HBME-1 was expressed in 88% of classic PC and 86% cases of FVPC, contrasting 
with 4% in FA [60].
The expression of HBME-1 in PC differs from surrounding benign thyroid tissues [66]. In a 
large study of 177 thyroid glands (including 53 PCs, 11 FVPC cases, 13 FCs and 100 benign 
thyroids), HBME-1 was expressed in 74% of PC and 89% of FVPC, but was not found (0%) 
in Graves’ disease or nodular colloid goitre [67]. Prasad et al. also confirmed the absence of 
HBME-1 in Graves’ disease and normal thyroid but experienced a single case (1%) of positive 
nodular goitre [63]. Higher expression rate in benign thyroid tissues (7.0%) has been reported 
by Nasr et al. [64]. The HMBE-1 reactivity in follicular neoplasms also differs remarkably 
between studies: 17% [67] vs. 26.7% [62] vs. 50.0% [63] vs. 85.7% [68] of FC and 4% [60] vs. 10% 
[63] vs. 11% [67] vs. 14.8% [62] vs. 64% [68] of FA.
The differences might be attributable to the evaluation (pattern: membranous only vs. 
membranous and cytoplasmic), cut-off threshold, selection of primary antibodies, epitope 
retrieval, dilution, incubation temperature and incubation time. Thus, although HBME-1 
is among the most sensitive and specific antigens in the PC diagnostics [61] and has been 
included in most diagnostic panels [58] for PC or thyroid cancer (predominated by PC), 
controversies remain.
Few, but promising reports are available on human trophoblast cell surface antigen TROP-2 in 
PC, which seems to be a reliable marker in histology and cytology, holding high specificity 
and sensitivity [61, 69–71]. The TROP-2 protein is absent from MC, follicular tumours and 
non-neoplastic thyroid tissue [70, 71], while it is present in 82.5% of PC. The limits of the 
marker include diagnostics of follicular variant which shows less frequent and focal staining. 
Nevertheless, the presence of 10% positive cells in a tumour indicates PC, and the heterogene-
ity is sufficiently low to apply TROP-2 IHC on FNA specimens [70]. Again, data on expression 
frequency are variable. Thus, in a recent study, TROP-2 was found in between 90.0 and 95.3% 
PC and 70.0% follicular variants [71]. However, other research groups have described signifi-
cantly less frequent reactivity: 50% [61].
CITED1 (the abbreviation for CREB (cAMP-response element-binding protein)/ p300 inter-
acting transactivator with glutamic acid/ aspartic acid-rich carboxy-terminal domain 1) 
protein, encoded by CITED1 gene, acts as transcriptional activator. The expression pattern is 
nuclear and cytoplasmic [63]. CITED1 enhances SMAD-mediated transcription by strength-
ening the interaction between DNA, transcription factors and coactivators (SMAD is an 
acronym coined by the fusion of names for the Sma gene in Caenorhabditis elegans and the 
“mothers against decapentaplegic” Mad gene in Drosophila). In association with SMAD path-
way, CITED1 promotes signalling via transforming growth factor beta (TGF-beta) molecular 
pathway. CITED1 also stabilises interaction between oestrogen receptors and histone acetyl-
transferase, enhancing oestrogen-dependent gene expression, and associates with chromatin 
in oestrogen-dependent way.
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CITED1 is expressed in PC [22]. Some authors consider it useful in differential diagnostics 
between PC, including follicular variant, and FA [43, 72] as expression of CITED1 in FA is con-
sidered rare [3]. However, CITED1 has been found in both benign and malignant pathologies. 
Thus, in a large study of 177 thyroid glands (including 53 PCs, 11 FVPC cases, 13 FCs and 100 
benign thyroids), CITED1 was expressed not only in 98% of PC, 100% of FVPC, and 86% of FC 
but also in 89% of Graves’ disease cases, 79% of nodular colloid goitre and 80% of FA [67]. More 
promising data were obtained in another large IHC study of 127 thyroid tumours, including 
49 classic PCs, 29 FVPC cases and 49 FAs. CITED1 was expressed in 90% of classic PC and 83% 
FVPC cases, contrasting with 16% of FA [60]. Similarly, CITED1 was expressed in 93% of PC, 25% 
of FC, 10% of FA and 8% of nodular goitre, but it was not found in normal thyroid glands and 
Graves’ disease cases [63]. Among 215 formalin-fixed, paraffin-embedded thyroid specimens, 
CITED1 was expressed in 87% PC and 50% FC while only 10% of FA and 24% of nodular goitre 
were positive, but cases of Graves’ disease and normal thyroid were invariably negative [63].
CITED1 expression is dependent on technological issues. One of the described rabbit antibod-
ies has been associated with increased background to such a degree that interferes with reli-
able evaluation. However, another rabbit antibody has also been considered as having lower 
sensitivity and specificity in comparison with HBME-1 and CK19 [60].
Knowing the role of CITED1 in PC and the epidemiological evidence of higher incidence in 
females, it is not surprising to find expression of oestrogen and progesterone receptors in 
papillary carcinoma. Expression of oestrogen receptor alpha and progesterone receptor has 
been reported in 19% and 38.7–57% of PC cases, correspondingly [73, 74].
Galectins represent a family of proteins that are defined by the capacity to bind beta-galac-
toside carbohydrates. Galectins are located in cell nuclei, cytoplasm or extracellular space. 
Galectins are classified into dimeric, tandem and chimera classes. Dimeric galectins, e.g., 
galectin-1, are simple homodimers. Tandem galectins contain one or more carbohydrate rec-
ognition domains in a single peptide chain. Chimeric class, represented only by galectin-3, 
has long non-lectin domain. Such chimeric molecule can exist as a monomer (at low con-
centration) or form multimers (at high concentration), if up to five monomers are linked by 
non-lectin domain. The physiologic effects are different: while monomers inhibit adhesion by 
blocking adhesion proteins, pentamers create intercellular bridges or link cells and extracel-
lular matrix.
Expression of galectin-3 in FA is rare [3]. Galectin-3 is more frequently seen in malignant 
thyroid tumours [75], and this finding has strong pathogenetic basis. Knockdown or antago-
nists of galectin-3 suppress the migratory capacity of PC cells. Galectin-3 is upregulated by 
hypoxia-inducible factor (HIF)-1 [76]. In PC, the expression rate has been estimated as 64.7% 
[65] vs. 69% [61] vs. 92% [67] or even 100% [77]. Lower rate has been reported in follicular vari-
ant: 33 vs. 92% in classic cases [67]. However, some authors describe close findings in classic or 
follicular variant. Thus, in a large IHC study of 127 thyroid tumours, including 49 classic PCs, 
29 FVPC cases and 49 FAs, galectin-3 was expressed in 96% of classic PC and 90% FVPC cases, 
contrasting with 18% in FA [60]. The expression frequency reached 97% in a small mixed 
group of carcinomas, comprising 22 PCs (16 classic and six FVPC cases), 3 FCs, 5 MCs and a 
single Hurtle cell carcinoma [75]. Among 13 FCs, the expression rate was 33% [67]. The stain-
ing pattern should be both nuclear and cytoplasmic [22]. Notably, benign reactive epithelial 
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and inflammatory cells in Hashimoto thyroiditis can express galectin-3 [22, 60]. No expres-
sion was found in Graves’ disease and nodular colloid goitre by Liu et al. [67]. However, 
other research groups have noted the presence of galectin-3 in 55% of nodular goitre and 
7% of Graves’ diseases cases while normal thyroid tissues were invariably negative [63]. FA 
has been described as negative [67] or occasionally (18%) positive [60]. In general, galectin-3 
has been found in 10% [63] vs. 30% [75] vs. 43% [77] FA, more frequently (80%) in Hurtle cell 
adenomas [77]. Even the authors reporting less frequent positivity in FA, consider galectin-3 
as a second-line marker due to lower specificity and sensitivity [60].
Along with CK19 and galectin-3, galectin-1 is more frequently expressed in PC than in 
FA. Loss of galectin-1 activity suppresses proliferation, migration and invasion [78]. In cell 
cultures, galectin-1 has been evaluated as the target for vectorised contrast agent, bearing 
peptide-conjugated ultrasmall superparamagnetic iron oxide particles for MRI [79].
Glypicans along with syndecans represent the major protein families of heparin sulphate 
proteoglycans. Glypicans are involved in developmental processes as well as regulation of 
cell signalling by Wnt and Hedgehog pathways. Glypican-3 is more frequently expressed in 
malignant thyroid tumours. Among 17 FA, the expression rate was 24%. Higher positivity 
rate (81%) was observed in a small mixed group of carcinomas, comprising 22 PCs, 3 FCs, 5 
MCs and one case of Hurtle cell carcinoma [75]. In a larger group, glypican-3 was found in 
100% (20/20) of FC and 70% (48/69) of PC [80].
PCs are characterised by upregulation of CD44 and its ligand osteopontin. Expression of 
osteopontin in PC is statistically significantly higher than normal thyroid tissue, colloid goitre 
and FA. In addition, the presence and intensity of osteopontin expression correlates with pro-
liferation activity [81], capacity to invade and occurrence of adverse prognostic factors such as 
lymph node metastases and large size of the tumour [82]. Expression of osteopontin is found 
in 83.3% of PC, 70.0% of benign thyroid nodules and 50.0% of normal thyroid tissues [83]. 
Limited amount of information is available on osteopontin in FC, but upregulation has been 
shown in dogs [84]. In MC, osteopontin is expressed in 78.4% of cases and shows association 
with good prognostic features [85]. The levels of bone sialoprotein are increased in PC. Thus, 
expression of bone sialoprotein is found in 87.9% of PC, 55.0% of benign thyroid nodules and 
42.5% of normal thyroid tissues [83]. PC is characterised by statistically significant cytoplas-
mic and membranous upregulation of vitamin D receptor in comparison to non-neoplastic 
thyroid tissues. Cancer cells also possess vitamin-D inactivating 24-hydroxylase but not acti-
vating enzyme, namely, 1-alpha-hydroxylase. Overexpression of 24-hydroxylase is associated 
with extrathyroid invasion and lymph node metastases [74].
Regarding CD44 variant 6 protein, the positive cell fraction in PC constitutes 80.3% while 
only 37.1% of cells in benign thyroid nodules and 22.9% of normal thyroid epithelial cells are 
positive [86]. Stem cell marker CD44 is involved in epithelial-mesenchymal transition (EMT), 
characterised by loss of epithelial markers, e.g., E-cadherin, and appearance of mesenchymal 
proteins, e.g., vimentin. Expression of vimentin was found in 53.8% of PC and 75% of FC [87]. 
PCs feature loss of E-cadherin in contrast to surrounding benign thyroid tissues. Nevertheless, 
E-cadherin along with CD56 is upregulated in FA [88]. However, if cancer is assessed sepa-
rately, not within the context with surrounding tissues, E-cadherin is still retained. Thus, 
expression of E-cadherin was found in 84.6% of PC and 75% of FC [87].
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Claudins are another class of EMT-associated proteins [89]. In FC, transmembrane tight junc-
tion protein claudin is dislocated from membrane to nucleus. Switch in subcellular compart-
mentalisation leads to increased proliferation, invasion and migration [90].
Among cytokeratins, CK19 has attracted attention. Intense expression of CK19 is considered 
a valuable diagnostic marker in PC [91], although it is the least specific marker of malignancy 
[22, 59]. In PC, reported expression rates of CK19 range between 45.6% [65], 83.3% [61] and 
84.6% [87]. Expression of CK19 was found in 25% of FC [87]. However, in a large study of 177 
thyroids (including 53 PCs, 11 FVPC cases, 13 FCs and 100 benign glands), CK19 was found in 
78% of PC, 22% of follicular variants, but was absent from FC, FA, Graves’ disease cases and 
nodular colloid goitre [67]. Promising data were obtained in another IHC study of 127 thyroid 
tumours, including 49 classic PC, 29 FVPC cases and 49 FA. CK19 was expressed in 100% of 
classic PC and 90% FVPC cases, contrasting with 14% of FA [60]. Nevertheless, in another 
study, CK19 was found in 100% PC and even 68.4% of benign thyroid tissues [64]. In a signifi-
cant cohort of 215 thyroids, CK19 was expressed in 72% of PC, 50% of FC, 5% of FA, 31% of 
nodular goitre, 0% of Graves’ disease and 7% of normal thyroids [63].
CK19 is considered to have high sensitivity but lower specificity in the differential diag-
nosis between PC and FA. However, not mere presence but also the intensity and distri-
bution of expression matters. The expression in PC tends to be strong and diffuse while 
FA shows focal and weaker staining. The expression in nodular hyperplasia and normal 
thyroid tissues also tends to be focal and weak [60]. The comparison between nodule and 
surrounding tissues would be important. In addition, PC is positive for pancytokeratin 
and CK7, but negative for CK20—a fact that in rare circumstances is helpful to distinguish 
between PC and thyroid metastases from a colorectal adenocarcinoma known to express 
CK20 [22].
In contrast with surrounding benign thyroid tissues, PC is characterised by downregulation 
of CD56 [59, 88]. The frequency of CD56 loss ranges from 93.9% in classic PC to 73.3% in FVPC 
cases [65]. In contrast, CD56 is upregulated in FA [88].
Regarding regulation of cell proliferation and apoptosis, PC is associated with increased 
expression of phosphorylated histone H3 and cyclin D1. Metastatic PCs exhibit upregu-
lated caspase-3 and loss of anti-apoptotic Bcl-2 [92]. Cyclins A and B1 are found in PC as 
well [93]. Autophagy-related protein Beclin-1 is more frequently seen in thyroid carcinomas. 
The expression rate is 98.9% in PC and 57.1% in FC while only 21.4% of FAs are positive for 
Beclin-1. The level of Beclin-1 correlates with proliferation activity by Ki-67 [68]. Survivin is 
more frequently expressed in carcinomas and is associated with the biological potential of the 
neoplasm [94]. Cytoplasmic location of p27 has been observed in PC [95], and p27 along with 
galectin has been advised to discriminate between FA and FC [96].
PC is characterised by complete or almost complete loss of c-kit/CD117 protein contrasting 
with benign thyroid nodules and normal follicular epithelium [97].
Aberrant membranous expression of CD20 has recently been reported in PC [98, 99]. In a 
small group of PC, expression was found in 5/22 (23%) tumours [99]. The findings were con-
firmed in a large cohort of 538 PCs [98] disclosing reactivity in 10% of cases. Although CD20 
was associated with less aggressive morphological features of PC, expression in anaplastic 
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thyroid cancers was observed with similar frequency (6–20%) as in PC. FAs (47) were neg-
ative. Positivity of CD20 was not associated with other B lymphocyte lineage markers as 
CD79alpha or PAX5 [98] but was confirmed by two different clones of primary antibody [99].
Neuroendocrine differentiation is the hallmark of MC that is positive for chromogranin A 
in 92.9% of cases [100]. Regarding the other regional causes of chromogranin A-positive 
mass lesions, parathyroid adenoma (that can occur intrathyroidally) and parathyroid 
hyperplasia are characterised by expression rates of 28/28 and 7/8 [100]. IHC panels should 
include calcitonin and carcinoembryonic antigen CEA (to identify MC with 100% speci-
ficity, as reported by Wuertz et al.) and parathyroid hormone that is expressed in 72.2% 
parathyroid nodules [100].
In most MCs, calcitonin is present [101]. In the rare cases of non-secretory MC, IHC diag-
nosis is still possible by panel of calcitonin, CEA and chromogranin A [102]. Among 75 MC, 
calcitonin receptor was expressed in 82.7% of cases. It showed strong positive correlation 
with calcitonin (p = 0.001) and osteocalcin (p = 0.009) as reported by Cappagli et al. [103]. 
CEA expression is characteristic and is mostly widespread and moderate to strong by inten-
sity [104]. Presence of CD56 has been reported [101].
Clusterin is another lineage-specific IHC marker, expressed in C cells, C cell hyperplasia and 
primary and metastatic MC. In addition, prognostic value of clusterin score has been reported, 
with inverse correlation between clusterin score and presence of lymph node metastases 
[105]. Survivin and X-linked inhibitor of apoptosis (XIAP) are expressed in C cells and MC 
and are associated with worse survival [106]. Expression of HIF-1alpha is another prognostic 
marker. Positive expression has been shown to be associated with worse 5-year survival and 
progression free survival [107]. Stem cell markers CD133 and CD44 are unfavourable prog-
nostic predictors. Both CD133 and CD44 are independent factors associated with worse over-
all survival, while CD44 is also significantly associated with recurrence-free survival [108]. 
Expression of somatostatin receptors 2A and 5 correlates with advanced stages [109]. Heat 
shock proteins HSP70, HSP90 and GRP78 are upregulated in MC in comparison with normal 
thyroid tissues [110]. Upregulation of cancer/testis antigens is seen, contrasting with negative 
normal thyroid tissues and goitre as well as with rare expression in PC and FC. However, 
poorly differentiated and anaplastic carcinomas are also positive [111].
Panel Aim Cohort References
HBME-1, galectin-3, CK19 FVPC vs. FA 157 thyroid tumours, 5 normal glands [72]
HBME-1, galectin-3, CITED1 FVPC vs. FA 157 thyroid tumours, 5 normal glands [72]
HBME-1, CK19
Second line: CITED1, galectin-3
PC vs. FA 127 thyroid tumours: 49 classic PC, 29 
FVPC, 49 FA
[60]
HBME-1, CK19 PC vs. benign thyroid 
tissues
51 PC, 57 benign cases [64]
HBME, Hector Battifora mesothelial epitope; CK, cytokeratin; CITED1, the abbreviation for CREB (cAMP-response 
element-binding protein)/ p300 interacting transactivator with glutamic acid/ aspartic acid-rich carboxy-terminal 
domain 1; FVPC, follicular variant of papillary carcinoma; FA, follicular adenoma and PC, papillary carcinoma.
Table 2. Immunohistochemical panels in the diagnostics of thyroid nodules.
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Recognising the diversity of thyroid nodules and variability of IHC data, panel diagnostics is 
advised (see examples in Table 2).
5. miRNAs in thyroid tumours
Biochemical and biological alterations of cancer cells are largely supported by non-coding 
RNA (ncRNA) dysregulation in the tumour. Non-coding RNAs lack an open-reading frame 
and do not have protein-coding ability. Based on the size of the functional RNA molecule, 
regulatory ncRNAs are classified as long ncRNAs and small ncRNAs or microRNAs [112]. 
MicroRNAs (miRNA) are small, evolutionary conserved, single-stranded, non-coding RNA 
molecules (approximately 22 nucleotides in length) that bind target mRNA to regulate gene 
expression [113, 114]. MicroRNAs are involved in various physiological and pathological func-
tions, such as apoptosis, cell proliferation and differentiation, which indicate their functionality 
in carcinogenesis as tumour suppressor genes or oncogenes [115]. Up or downregulation of 
miRNA can influence the tumorigenic outcome depending on the role(s) of the target genes on 
vital signalling processes [116].
The most often upregulated miRNAs in PC are miR-146b, miR-222, miR-221 and miR-181b. 
Overexpressed miR-146b targets retinoic acid receptor beta (RARβ) and reduces expression of 
this gene leading to increased tumour aggressiveness and extrathyroidal invasion [117–120]. 
MiR-221 and miR-222 target tumour suppressor and cell cycle regulator p27. Reduced expres-
sion of p27 results in increased proliferation of tumour cells. These processes are related to 
aggressive behaviour of tumour, extrathyroidal invasion and spread to lymph nodes [117–
120]. MiR-181b is also overexpressed in PC compared to normal thyroid tissue. MiR-181b 
inhibits expression of cylindromatosis CYLD gene, which acts as tumour suppressor and nor-
mally induces apoptosis [118, 121].
The most often downregulated miRNAs in PC are miR-145, miR-451, miR-613 and miR-137. 
MiR-145 acts as a tumour suppressor in thyroid cancer, and its downregulation enhances can-
cer growth via several pathways [118]. MiR-451 functions as a tumour suppressor by target-
ing the PI3/AKT pathway. Downregulation of miR-451a is associated with aggressive tumour 
course and the presence of extrathyroidal invasion [118, 120]. In PC, miR-613 is involved in 
cell proliferation and invasion [117, 118], but downregulated miR-137 leads to increased cel-
lular proliferation, invasion and migration [118].
The miRNAs found in FC are also frequently present in other subtypes of thyroid cancer 
[120]. MiR-199a-5p is downregulated, but miR-197 and miR-346 are upregulated in FC result-
ing in increased cancer cell proliferation [118].
Many miRNAs have been found to be dysregulated in thyroid cancer, but only few miRNAs 
are exclusively associated with anaplastic thyroid cancer [118]. Loss of miR-200 expression in 
anaplastic carcinoma results in EMT that represses the epithelial features of cancer cells and 
disrupts the cell-cell adhesion mediated by loss of E-cadherin. This process enables cells to 
migrate and invade [116, 118, 120].
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In MC, miR-21 is recently studied. It is downregulated, especially in the aggressive cases 
[120]. MiR-129-5p is significantly downregulated in MC compared to normal tissue leading to 
increased cellular invasion and migration [118].
6. Systemic inflammatory reaction in thyroid carcinoma patients
Systemic inflammatory response (SIR) is induced by different types of cancer [122, 123]. 
Interaction between the tumour and the host inflammatory response is crucial in cancer 
development [122, 124]. Many studies confirm the association between increased SIR and 
poor outcome in cancer patients [124, 125]. To evaluate SIR, different parameters are used: 
neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), concentration of 
acute phase proteins, clotting factors and albumins, e.g., Glasgow Prognostic Score (GPS) 
and others [123, 126]. The role of SIR in thyroid cancer is still poorly understood. Authors of 
several studies have suggested that increased NLR is associated with larger tumour size and 
increased recurrence risk of thyroid cancer [127, 128].
7. Conclusions
In conclusion, thyroid nodules represent an important problem in endocrine surgery as a fre-
quent finding inducing complicated differential diagnostics. In general population, such nodules 
are found in 3.7–7% by palpation and 42–67% by US. Cancer risk in thyroid nodule varies: 5% in 
masses found by palpation, 1.6–15% by US, 3.9–11.3% by CT, 5–6% by MRI and 30–50% by PET.
The epidemiological picture of thyroid carcinoma is characterised by growing incidence and 
stable or decreasing mortality, suggesting overtreatment of an indolent disease. However, 
mortality growth is seen in some countries, e.g., in Costa Rica (for 66.9%), Moldova (49.9%), 
Uruguay (47.9%), Latvia (26.2%), Ecuador (36.3%), New Zealand (14.5%) and Portugal 
(15.7%) for males and Colombia, Ecuador (both 17.8%) or Greece (13.3%) for females. In addi-
tion, SEER data disclose growing incidence of large carcinomas. Clinically, incidental thyroid 
nodules are reported less frequently than in dedicated research studies. Thus, true incidence 
growth can be related to risk factors such as changes in iodine supplementation, adiposity, 
oestrogens, parity, pregnancy-related increases in TSH levels, exposure to ionising radiation 
and chemicals, e.g., polybrominated diphenyl ethers, used as flame retardants.
The final diagnosis of thyroid tumours, dominated by benign follicular adenomas and malig-
nant papillary, follicular and medullary carcinomas, depends on FNA and histopathology. 
Classic morphology, based on invasion and nuclear features, substantiates the diagnosis in 
most cases and represents the basis of WHO diagnostic criteria.
A significant innovation is the definition of new entities in the recent WHO classification to 
designate thyroid tumours with controversial morphological appearance, doubtful invasion 
or questionable nuclear features. Follicular tumours that definitely lack invasion but exhibit 
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controversial nuclear structure are classified as non-invasive follicular thyroid neoplasm with 
papillary-like nuclear features. Follicular-patterned neoplasms with questionable invasion 
are called either follicular tumours of uncertain malignant potential if the nuclei are of non-
papillary type or well-differentiated tumour of uncertain malignant potential in other cases. 
These new entities provide pathologists with the long-awaited benefit of accurate diagnosis.
Ancillary methods include the widely accessible immunohistochemistry and rapidly develop-
ing field of miRNA analysis. HBME-1, TROP-2, CITED1 and CK19 can be helpful in diagnos-
tics of papillary carcinoma, while galectin-3 might serve as second-line marker. Expression of 
CD20 in PC has been recently reported. Distinction between FA and FC is difficult; HBME-1, 
p27 and galectin evaluation has been recommended. MC holds neuroendocrine differentiation.
Regarding miRNAs, PC is characterised by upregulation of miR-146b, miR-222, miR-221 
and miR-181b and downregulation of miR-145, miR-451, miR-613 and miR-137. FC features 
downregulated miR-199a-5p and upregulated miR-197 and miR-346. In MC, miR-21 and miR-
129-5p are downregulated.
Initial studies suggest that increased SIR can be poor prognostic factor in thyroid cancer.
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